| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Medical Research Council Group in Fetal and Neonatal Health and Development (S.L.B., V.K.M.H.), Departments of Biochemistry (S.L.B., V.K.M.H.) and Pediatrics (V.K.M.H.), University of Western Ontario, The Lawson Research Institute, London, Ontario, Canada N6A 4V2; and the Department of Pediatrics, University of North Carolina (A.J.D.), Chapel Hill, North Carolina 27514
Address all correspondence and requests for reprints to: Victor K. M. Han, M.D., Room H308, The Lawson Research Institute, 268 Grosvenor Street, London, Ontario, Canada N6A 4V2. E-mail: vhan{at}julian.uwo.ca
To examine the relationship between the expression of insulin-like growth factor (IGF)-binding protein-2 (IGFBP-2) and cell growth in a cell type with a defined IGF/IGFBP system, an ovine IGFBP-2 complementary DNA was overexpressed in C6 glioma cells. C6 cells produce IGFBP-3, IGFBP-4, a negligible amount of IGFBP-2, and IGF-I. An ovine IGFBP-2 complementary DNA was transfected into C6 cells, and nine colonies that stably expressed variable levels of IGFBP-2 messenger RNA were selected. Synthesis of corresponding levels of IGFBP-2 was confirmed by ligand blot and immunoblot analyses of conditioned media. Three clones exhibited significantly reduced growth rates, and the remainder showed growth rates similar to those of the wild-type C6 cells. The clones, which overexpressed high levels of IGFBP-2 and IGF-I, had growth rates similar to the wild-type cells, whereas the three clones that overexpressed IGFBP-2 without a concomitant increase in IGF-I had reduced growth rates. In addition, a cell-associated IGFBP was identified in the slow growing clones, but not in the wild-type or the fast growing clones. This cell-associated IGFBP was deduced to be IGFBP-5 based on its molecular size, detection of IGFBP-5 messenger RNA only in slow growing clones, and competition of its binding by heparin. Growth of the slow growing clone, C6BP2-1, could not be overcome by the addition of exogenous IGF-I, suggesting that the cell-associated IGFBP-5 was the dominant regulator of IGF action. These observations suggested that 1) in C6 glioma cells cellular growth is altered by a disturbance in the equilibrium between IGF-I and IGFBPs and/or the functional properties of the IGFBPs; and 2) C6 cells may have a limited capacity to modulate IGF/IGFBP expression in response to changes in endogenous expression of IGFBPs. Endogenous regulation of the balance between IGFs and IGFBPs may be a model of regulation of cellular growth in tumor cells.
This article has been cited by other articles:
![]() |
C. Iosef, T. Gkourasas, C. Y. H. Jia, S. S.-C. Li, and V. K. M. Han A Functional Nuclear Localization Signal in Insulin-Like Growth Factor Binding Protein-6 Mediates Its Nuclear Import Endocrinology, March 1, 2008; 149(3): 1214 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Martin and R. C. Baxter Expression of Insulin-Like Growth Factor Binding Protein-2 by MCF-7 Breast Cancer Cells Is Regulated through the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway Endocrinology, May 1, 2007; 148(5): 2532 - 2541. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Watson, P. Bialek, M. Anzo, J. Khosravi, S.-P. Yee, and V. K. M. Han Elevated Circulating Insulin-Like Growth Factor Binding Protein-1 Is Sufficient to Cause Fetal Growth Restriction Endocrinology, March 1, 2006; 147(3): 1175 - 1186. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoeflich, R. Reisinger, H. Lahm, W. Kiess, W. F. Blum, H. J. Kolb, M. M. Weber, and E. Wolf Insulin-like Growth Factor-binding Protein 2 in Tumorigenesis: Protector or Promoter? Cancer Res., December 1, 2001; 61(24): 8601 - 8610. [Full Text] [PDF] |
||||
![]() |
L. Wang, X. Ma, L.-C. C. Yeh, and M. L. Adamo Differential Regulation of IGF-Binding Protein Gene Expression by cAMP in Rat C6 Glioma Cells Endocrinology, September 1, 2001; 142(9): 3917 - 3925. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoeflich, S. Nedbal, W. F. Blum, M. Erhard, H. Lahm, G. Brem, H. J. Kolb, R. Wanke, and E. Wolf Growth Inhibition in Giant Growth Hormone Transgenic Mice by Overexpression of Insulin-Like Growth Factor-Binding Protein-2 Endocrinology, May 1, 2001; 142(5): 1889 - 1898. [Abstract] [Full Text] |
||||
![]() |
M. W. Elmlinger, M. H. Deininger, B. S. Schuett, R. Meyermann, F. Duffner, E. H. Grote, and M. B. Ranke In Vivo Expression of Insulin-Like Growth Factor-Binding Protein-2 in Human Gliomas Increases with the Tumor Grade Endocrinology, April 1, 2001; 142(4): 1652 - 1658. [Abstract] [Full Text] |
||||
![]() |
C. Duan, J. Ding, Q. Li, W. Tsai, and K. Pozios Insulin-like growth factor binding protein 2 is a growth inhibitory protein conserved in zebrafish PNAS, December 21, 1999; 96(26): 15274 - 15279. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |